NCT07430202 — Sidney Kimmel Comprehensive Cancer Center… cancer vaccine trial
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Registry record
| Registry ID | NCT07430202 ↗ |
|---|---|
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Collaborators | Dracen Pharmaceuticals, Inc., Cancer Research Institute, New York City, Fibrolamellar Cancer Foundation |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) |
| Enrollment | 27 participants (target) |
| Start date | 2026-09 |
| Primary completion | 2030-09 (est.) |
| Last registry update | 25 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07430202), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07430202?
NCT07430202 (A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)) is registered on ClinicalTrials.gov as Phase 1, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Is NCT07430202 recruiting?
As of the 2026-08-25 registry update, NCT07430202 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07430202?
The lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Collaborators: Dracen Pharmaceuticals, Inc., Cancer Research Institute, New York City, Fibrolamellar Cancer Foundation.
What condition does NCT07430202 study?
The registered condition is Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)). Primary completion is listed as 2030-09 (estimated).
Are results available for NCT07430202?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07430202.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.